350 related articles for article (PubMed ID: 12422135)
21. The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Dawson A; Davies JI; Struthers AD
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):29-36. PubMed ID: 15038411
[TBL] [Abstract][Full Text] [Related]
22. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
Pfeffer MA
Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
[TBL] [Abstract][Full Text] [Related]
23. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
Kalidindi SR; Tang WH; Francis GS
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
[TBL] [Abstract][Full Text] [Related]
24. The role of aldosterone receptor blockade in the management of cardiovascular disease.
Liew D; Krum H
Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
George J; Struthers AD
Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
[TBL] [Abstract][Full Text] [Related]
26. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
[TBL] [Abstract][Full Text] [Related]
27. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
29. Aldosterone receptor blockade: a therapy resurrected.
Sica DA
Heart Dis; 2003; 5(2):85-8. PubMed ID: 12713674
[No Abstract] [Full Text] [Related]
30. Eplerenone: a new selective aldosterone receptor antagonist.
Weinberger MH
Drugs Today (Barc); 2004 Jun; 40(6):481-5. PubMed ID: 15349128
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Struthers A; Krum H; Williams GH
Clin Cardiol; 2008 Apr; 31(4):153-8. PubMed ID: 18404673
[TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
33. Aldosterone receptor antagonists for heart failure: current status, future indications.
Pitt B; Rajagopalan S
Cleve Clin J Med; 2006 Mar; 73(3):257-60, 264-8. PubMed ID: 16548448
[TBL] [Abstract][Full Text] [Related]
34. The pathophysiology of aldosterone in the cardiovascular system.
Rocha R; Funder JW
Ann N Y Acad Sci; 2002 Sep; 970():89-100. PubMed ID: 12381544
[TBL] [Abstract][Full Text] [Related]
35. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
37. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
[No Abstract] [Full Text] [Related]
38. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
Ajani AE; Marwick TH; Krum H
Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
[TBL] [Abstract][Full Text] [Related]
39. The use of aldosterone receptor blockers in the treatment of hypertension.
Weinberger MH
J Clin Hypertens (Greenwich); 2004 Nov; 6(11):632-5. PubMed ID: 15538096
[TBL] [Abstract][Full Text] [Related]
40. [Roll of aldosterone in pathogenesis of kidney disorders].
Kitamura K; Tomita K
Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1428-34. PubMed ID: 16097603
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
